ABOUT THIS STUDY
- Subjects that will be included in this post marketing surveillance study must be consistent with the approved label indication of Torisel in the Philippines.
- As per approved label indication, patients diagnosed with advanced renal cell carcinoma will be the ones eligible to participate in the study.
- The decision to prescribe Torisel will necessarily precede and will be independent of the decision to enroll the patient into the study.
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- Subjects with conditions that are contraindicated with Torisel based on the approved
local product document in the Philippines will be excluded in this study. This
condition includes: Patients with bilirubin >1.5 x ULN.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New York, New York
- Toronto, Ontario
- Durham, North Carolina